Company: RGBP
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001641172-25-022884
Chunk: 2

Company: Regen BioPharma Inc
Filing Date: 2025-08-11
Form: 10-Q
Item: Part I, Item 1
Chunk 2
---
 6, 2023, the Company filed a Certificate of Amendment (the “ Certificate of Amendment”) to the Company’s Certificate
of Incorporation to effect a reverse stock split of its issued Common Stock in the ratio of 1-for-1,500 (the “ Reverse Stock Split”).
As a result of the Reverse Stock Split, the total number of shares of common stock held by each shareholder was converted automatically
into the number of whole shares of common stock equal to (i) the number of shares of common stock held by such shareholder immediately
prior to the Reverse Split, divided by (ii) 1,500, and then rounded up to the nearest whole number.

The
historical financial statements have been retroactively adjusted to reflect a 1 for 1500 reverse stock split

Derivative
Liability

The
Company analyzes the conversion feature of Convertible Notes for derivative accounting consideration under ASC 815-15 “ Derivatives
and Hedging. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained
in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change
in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying
amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model.

The
Black Scholes pricing model used to determine the Derivative Liability on convertible notes issued by the Company in which an embedded
derivative is recognized as of June 30, 2025 utilized the following inputs:

SCHEDULE
OF DERIVATIVE LIABILITY ON CONVERTIBLE NOTES USING BLACK SCHOLES PRICING MODEL

  Schedule of Derivative liability                          
  Risk Free Interest Rate               4.24                
  Expected Term                         0.18 – ( 5.16) Yrs  
  Expected Volatility                   184.01              
  Expected Dividends                    -                   

Income
Taxes

The
Company accounts for income taxes using the liability method prescribed by ASC 740, “ Income Taxes.” Under this method, deferred
tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities
using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation
allowance to offset deferred tax assets if based on the